Company
Headquarters: Taipei City, Taiwan
TW$4.25 Billion
TWD as of July 1, 2024
US$130.4 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $178.02 B |
| Stryker Corporation | $126.48 B |
| Boston Scientific Corporation | $112.32 B |
| Medtronic | $98.95 B |
| Edwards Lifesciences Corporation | $55.63 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region. The company offers its products under the Ortho-K myopia management lens, HiClear gas permeable (GP) lens, Briomoist lens care systems, SynergEyes hybrid lens, and Large Diameter GP lens. It also provides OEM/ODM collaboration services. The company is based in Taipei City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Brighten Optix Corp has the following listings and related stock indices.
Stock: TWSE: 6747 wb_incandescent